Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug

Abstract:
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.

A Starpharma dendrimer combined with a widely-used cancer drug (doxorubicin) has achieved a significant extension of the drug's plasma half-life and a marked reduction in drug toxicity compared to administration of the drug alone. In this proof-of-concept animal study the efficacy of the dendrimer-drug construct was equivalent to that of the drug alone.

Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug

Melbourne, Australia | Posted on December 17th, 2008

Doxorubicin was selected to illustrate the delivery technique because of its wide use as an anticancer agent, having application in Hodgkin's lymphoma, some leukemias, as well as cancers of the breast, lung, and ovaries. The clinical use of doxorubicin is often constrained by its cardiac toxicity which may result in congestive heart failure and dilated cardiomyopathy.

In Starpharma's recent study, an animal cancer-model ("xenograft") showed that Starpharma's dendrimer-doxorubicin construct (SPL8181) achieved the same inhibition of human breast-cancer tissue as doxorubicin alone, but with markedly reduced cardiac toxicity. Blinded histopathological examination of cardiac tissue samples from the dosed animals revealed significantly lower cardiotoxicity (p=0.019) in the dendrimer-doxorubicin construct treatment group (toxicity in 14% of samples) compared to a doxorubicin-only treatment group (toxicity in 86% of samples). Signs of reduced toxicity in other organs were also observed for the animals dosed with the dendrimer-based molecule compared to doxorubicin alone.

Starpharma's delivery technology works by attaching multiple drug molecules to the surface of a dendrimer nanoparticle. The result is that the dendrimer nanoparticle can target the drug to the tumour, in preference to other organs. This effect is illustrated for a second cancer molecule in Figure 3. Additionally Starpharma's proprietary dendrimer technology has been engineered to allow for the drug payload to be preferentially released from the nanoparticle in close proximity to the tumour.

Starpharma CEO, Dr Jackie Fairley said "Starpharma has already formed a number of partnerships based on its drug-delivery technology, including a dermal program with Stiefel Laboratories. The technology has application for both small molecule drugs and protein therapeutics and Starpharma is in advanced discussions with additional potential partners who have an interest in using it to improve the delivery, efficacy, and toxicity profile of their products."

The animal studies were conducted in collaboration with Associate Professor Chris Porter of the Victorian College of Pharmacy and Dr Carleen Cullinane of the Peter MacCallum Cancer Centre.

Starpharma has already taken a dendrimer-based drug into clinical trials conducted to US FDA requirements: VivaGel(R) vaginal microbicide is currently in Phase II clinical trials, and is the subject of a license agreement with Durex(R) condoms for use as a condom coating.

####

About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For more information, please click here

Contacts:
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704

Ben Rogers
Company Secretary
TEL: +61-3-8532-2702

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE